01:15 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients (95%) who received 10 or 20 million cells of...
01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
18:59 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Asterias raises $10.4M in registered direct offering

On Oct. 19, Asterias Biotherapeutics Inc. (NYSE-M:AST) closed a registered direct offering led by Chardan, raising $10.4 million through the sale of 4 million shares at $2.60. The company said it will use the funds...
23:51 , May 25, 2017 |  BC Extra  |  Company News

Management tracks

Epigenetics play Constellation Pharmaceuticals Inc. (Cambridge, Mass.) named Jigar Raythatha president and CEO. He was CBO at Jounce Therapeutics Inc. (NASDAQ:JNCE), and was previously Constellation's head of corporate development. Former Constellation CEO Keith Dionne has...
19:58 , May 5, 2017 |  BC Week In Review  |  Clinical News

DMC recommends continuation of Ph I/IIa of AST-OPC1 for SCI

Asterias Biotherapeutics Inc. (NYSE-M:AST) said a DMC recommended enrollment continuation of the 10 and 20 million cell cohorts of AST-OPC1 in the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI). The open-label,...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Additional Phase I/IIa data

Data from 5 patients with a complete cervical SCI who received a single injection of 10 million cells of AST-OPC1 in the open-label, dose-escalation, U.S. Phase I/IIa SCiStar trial showed that all 5 patients achieved...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Phase I/IIa data

Researchers at Keck Medicine of the University of Southern California reported data from 1 patient with a cervical SCI in the open-label, dose-escalation, U.S. Phase I/IIa SCiStar trial showing that a single injection of 10...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Phase I/IIa ongoing

Asterias said a DMC recommended continuation to the third and highest dose cohort in the open-label, U.S. Phase I/IIa SCiStar trial evaluating single injections of 2 million or 10 million cells of AST-OPC1 and 2...
07:00 , Jul 18, 2016 |  BC Extra  |  Company News

Management tracks

Cancer and neurology company e-Therapeutics plc (LSE:ETX) said Malcolm Young resigned as CEO and a director. The company is searching for a replacement. Gene therapy company Calimmune Inc. (Tucson, Ariz.) promoted Jeffrey Bartlett to CSO...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...